AstraZeneca Pharma India Ltd Stock Price Today (NSE: ASTRAZEN)
Fundamental Score
AstraZeneca Pharma India Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
AstraZeneca Pharma India Ltd share price today is ₹8930.50, up +0.00% on NSE/BSE as of 17 February 2026. AstraZeneca Pharma India Ltd (ASTRAZEN) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹22.61K (Cr). The 52-week high for ASTRAZEN share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 97.79x, ASTRAZEN is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 23.63% and a debt-to-equity ratio of 0.04.
AstraZeneca Pharma India Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
AstraZeneca Pharma India Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
AstraZeneca Pharma Share Price: A Financial Stability Analysis
One unique aspect of the pharmaceutical industry is its reliance on patent protection and brand recognition to maintain profitability. Today, we're performing a financial stability analysis on AstraZeneca Pharma India Ltd, considering its current financial metrics. The AstraZeneca Pharma share price is currently trading at ₹8557.5, a figure that needs to be contextualized within the broader market and the company's financial health. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.
A crucial metric to consider is the Price-to-Earnings (PE) ratio. AstraZeneca Pharma's PE of 97.79 is significantly higher than the sector average, which often indicates that investors have high expectations for future earnings growth. Whether those expectations are justified requires a deeper dive into the company's growth prospects, pipeline strength, and competitive landscape.
In comparison to its peers, like
Mankind Pharma Ltd, differences in management quality become important. While quantitative metrics provide a snapshot, qualitative assessments of leadership and strategic decision-making can significantly influence long-term performance. Investigating management's track record in navigating regulatory hurdles and fostering innovation is important for understanding the premium valuation. Further research into Mankind Pharma's management style and efficiency in comparison to AstraZeneca would provide more perspective.AstraZeneca Pharma's Return on Capital Employed (ROCE) of 33.4% is a powerful indicator of its ability to generate profits from its investments. This high ROCE contributes to the company's economic moat, as it suggests a strong competitive advantage, potentially derived from patented drugs, strong branding, or efficient operations. A sustained high ROCE signals an ability to reinvest profits effectively and maintain a leading position. Furthermore, analyzing how efficiently AstraZeneca Pharma is utilizing its intellectual property compared to Balaxi Pharmaceuticals Ltd and Smruthi Organics Ltd can help illuminate the sources of its strong ROCE.
It's important to remember that this is an observational analysis based on publicly available data and industry understanding. Future performance will depend on various factors, including regulatory changes, competitive pressures, and the success of ongoing research and development efforts.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
AstraZeneca Pharma India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTRAZEN across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (23.63%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (33.40%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Robust Profit Growth (51.26%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (37.03%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (15.59% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (19.45% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (19.45% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (131.37x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹329.01 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 97.79x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 8.00%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
AstraZeneca Pharma India Ltd Financial Statements
Comprehensive financial data for AstraZeneca Pharma India Ltd including income statement, balance sheet and cash flow
About ASTRAZEN (AstraZeneca Pharma India Ltd)
AstraZeneca Pharma India Ltd (ASTRAZEN) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹22.61K (Cr). AstraZeneca Pharma India Ltd has delivered a Return on Equity (ROE) of 23.63% and a ROCE of 33.40%. The debt-to-equity ratio stands at 0.04, reflecting the company's capital structure. Investors tracking ASTRAZEN share price can monitor key metrics including P/E ratio, promoter holding of 75.00%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
ASTRAZEN Share Price: Frequently Asked Questions
What is the current share price of AstraZeneca Pharma India Ltd (ASTRAZEN)?
As of 17 Feb 2026, 10:08 am IST, AstraZeneca Pharma India Ltd share price is ₹8930.50. The ASTRAZEN stock has a market capitalisation of ₹22.61K (Cr) on NSE/BSE.
Is ASTRAZEN share price Overvalued or Undervalued?
ASTRAZEN share price is currently trading at a P/E ratio of 97.79x, compared to the industry average of 31.77x. Based on this relative valuation, the AstraZeneca Pharma India Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ASTRAZEN share price?
The 52-week high of ASTRAZEN share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the AstraZeneca Pharma India Ltd share price?
Key factors influencing ASTRAZEN share price include quarterly earnings growth (Sales Growth: 37.03%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is AstraZeneca Pharma India Ltd a good stock for long-term investment?
AstraZeneca Pharma India Ltd shows a 5-year Profit Growth of 19.45% and an ROE of 23.63%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.04 before investing in ASTRAZEN shares.
How does AstraZeneca Pharma India Ltd compare with its industry peers?
AstraZeneca Pharma India Ltd competes with major peers in the Pharmaceuticals. Investors should compare ASTRAZEN share price P/E of 97.79x and ROE of 23.63% against the industry averages to determine competitive standing.
What is the P/E ratio of ASTRAZEN and what does it mean?
ASTRAZEN share price has a P/E ratio of 97.79x compared to the industry average of 31.77x. Investors pay ₹98 for every ₹1 of annual earnings.
How is ASTRAZEN performing according to Bull Run's analysis?
ASTRAZEN has a Bull Run fundamental score of 65.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ASTRAZEN belong to?
ASTRAZEN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting AstraZeneca Pharma India Ltd share price.
What is Return on Equity (ROE) and why is it important for ASTRAZEN?
ASTRAZEN has an ROE of 23.63%, which indicates excellent management efficiency. ROE measures how efficiently AstraZeneca Pharma India Ltd generates profits from shareholders capital.
How is ASTRAZEN debt-to-equity ratio and what does it indicate?
ASTRAZEN has a debt-to-equity ratio of 0.04, which indicates conservative financing with low financial risk.
What is ASTRAZEN dividend yield and is it a good dividend stock?
ASTRAZEN offers a dividend yield of 0.35%, meaning you receive ₹0.35 annual dividend for every ₹100 invested in AstraZeneca Pharma India Ltd shares.
How has ASTRAZEN share price grown over the past 5 years?
ASTRAZEN has achieved 5-year growth rates of: Sales Growth 15.59%, Profit Growth 19.45%, and EPS Growth 19.45%.
What is the promoter holding in ASTRAZEN and why does it matter?
Promoters hold 75.00% of ASTRAZEN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in AstraZeneca Pharma India Ltd.
What is ASTRAZEN market capitalisation category?
ASTRAZEN has a market capitalisation of ₹22605 crores, placing it in the Large-cap category.
How volatile is ASTRAZEN stock?
ASTRAZEN has a beta of N/A. A beta > 1 suggests the AstraZeneca Pharma India Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ASTRAZEN operating profit margin trend?
ASTRAZEN has a 5-year average Operating Profit Margin (OPM) of 14.65%, indicating the company's operational efficiency.
How is ASTRAZEN quarterly performance?
Recent quarterly performance shows AstraZeneca Pharma India Ltd YoY Sales Growth of 37.03% and YoY Profit Growth of 51.26%.
What is the institutional holding pattern in ASTRAZEN?
ASTRAZEN has FII holding of 2.74% and DII holding of 5.26%. Significant institutional holding often suggests professional confidence in the AstraZeneca Pharma India Ltd stock.